Contributions
Abstract: EP1395
Type: ePoster
Abstract Category: Clinical aspects of MS - 8 Clinical assessment tools
Background: Cognitive performance is a sensitive indicator of disease progression in Multiple Sclerosis (MS). The BICAMS psychometric characteristics have not been established in Arabic-speaking populations.
Objective: To validate and provide normative and psychometric data for the BICAMS in Arabic.
Methods: In this cross sectional study, mBICAMS will be administered to 184 healthy subjects with no history of neurological disorders, traumatic brain injury, psychiatric disorders, and cognitive impairment, aged 16-90 years [n=62; age 16-35, n=72; 36-65, n=50; 66-90 years], and 50 MS patients. Additional screening using the Hopkins Symptom Checklist-25 (depression score ³ 3.3, excluded) and Montreal Cognitive Assessment (score< 26, excluded) is performed. mBICAMS consists of 3 tests; the Symbol Digit Modalities Test (SDMT), the Brief Visuospatial Memory Test-Revised (BVMTR), and a newly developed Verbal Memory Arabic Test (VMAT) - a learning test of 15 culturally sensitive words, consisting of five learning trials, immediate and delayed trials, with and without cues, and a recognition trial). Cognitive reserve and non-verbal intelligence quotient are also assessed. The BICAMS validation method is based on Benedict et al. 2012' recommendations.
Results: To date, 93 participants were screened (10 excluded; for drug dependence, psychiatric disorders, antidepressant use, or high depression score, and 5 participants dropped out). Of these participants, 77 healthy subjects (43 females and 34 males) and 1 MS patient completed the study, and retest has been performed on 45 of these subjects after 21 days on average (M age 29.5±10.8 years). Most participants (80%) obtained medium cognitive reserve scores (M 105.86±12.78), and showed average nonverbal intelligence quotient (105.78±16.03). SDMT yielded 61.38±8.96 correct answers (test-retest r=0.64). On the VMAT, mean number of words recalled on the first 5 learning trials was 10.99±1.49, short delay recall 11.23±2.29, cued recall 11.53±2.15, long delay recall 11.88±2.29, cued recall 11.99±2.24, recognition trial 43.45±1.98 out of 45 words). VMAT showed acceptable test-retest reliability; r=0.43. On the BVMT-R, participants scored 5.42±2.42 on trial 1, 8.75±2.42 trial 2, and 10.42±1.88 trial 3 (test-retest Cohen's d=1.15).
Conclusions: Recruitment and data collection are ongoing. Validating the mBICAMS will allow more accurate clinical use and research utilizations of these measures in the Arab world MS patients.
Disclosure:
We disclose that S.K. and H.D. have received research grants from Novartis.
H.D. furthermore received honoraria for lectures from Novartis, travel awards from Novartis, Merck and Genzyme, and research grants from MENACTRIMS.
B.Y. received honoraria for lectures from Bayer, Genzyme, Merck-Serono,
Novartis, Genpharm, Biogen, research grants from Bayer, Merck-Serono, Novartis, Biogen, Pfizer and he serves on the Advisory board with Honoraria from Bayer, Novartis, Merck-Serono, Biogen, Genzyme, Genpharm.
Abstract: EP1395
Type: ePoster
Abstract Category: Clinical aspects of MS - 8 Clinical assessment tools
Background: Cognitive performance is a sensitive indicator of disease progression in Multiple Sclerosis (MS). The BICAMS psychometric characteristics have not been established in Arabic-speaking populations.
Objective: To validate and provide normative and psychometric data for the BICAMS in Arabic.
Methods: In this cross sectional study, mBICAMS will be administered to 184 healthy subjects with no history of neurological disorders, traumatic brain injury, psychiatric disorders, and cognitive impairment, aged 16-90 years [n=62; age 16-35, n=72; 36-65, n=50; 66-90 years], and 50 MS patients. Additional screening using the Hopkins Symptom Checklist-25 (depression score ³ 3.3, excluded) and Montreal Cognitive Assessment (score< 26, excluded) is performed. mBICAMS consists of 3 tests; the Symbol Digit Modalities Test (SDMT), the Brief Visuospatial Memory Test-Revised (BVMTR), and a newly developed Verbal Memory Arabic Test (VMAT) - a learning test of 15 culturally sensitive words, consisting of five learning trials, immediate and delayed trials, with and without cues, and a recognition trial). Cognitive reserve and non-verbal intelligence quotient are also assessed. The BICAMS validation method is based on Benedict et al. 2012' recommendations.
Results: To date, 93 participants were screened (10 excluded; for drug dependence, psychiatric disorders, antidepressant use, or high depression score, and 5 participants dropped out). Of these participants, 77 healthy subjects (43 females and 34 males) and 1 MS patient completed the study, and retest has been performed on 45 of these subjects after 21 days on average (M age 29.5±10.8 years). Most participants (80%) obtained medium cognitive reserve scores (M 105.86±12.78), and showed average nonverbal intelligence quotient (105.78±16.03). SDMT yielded 61.38±8.96 correct answers (test-retest r=0.64). On the VMAT, mean number of words recalled on the first 5 learning trials was 10.99±1.49, short delay recall 11.23±2.29, cued recall 11.53±2.15, long delay recall 11.88±2.29, cued recall 11.99±2.24, recognition trial 43.45±1.98 out of 45 words). VMAT showed acceptable test-retest reliability; r=0.43. On the BVMT-R, participants scored 5.42±2.42 on trial 1, 8.75±2.42 trial 2, and 10.42±1.88 trial 3 (test-retest Cohen's d=1.15).
Conclusions: Recruitment and data collection are ongoing. Validating the mBICAMS will allow more accurate clinical use and research utilizations of these measures in the Arab world MS patients.
Disclosure:
We disclose that S.K. and H.D. have received research grants from Novartis.
H.D. furthermore received honoraria for lectures from Novartis, travel awards from Novartis, Merck and Genzyme, and research grants from MENACTRIMS.
B.Y. received honoraria for lectures from Bayer, Genzyme, Merck-Serono,
Novartis, Genpharm, Biogen, research grants from Bayer, Merck-Serono, Novartis, Biogen, Pfizer and he serves on the Advisory board with Honoraria from Bayer, Novartis, Merck-Serono, Biogen, Genzyme, Genpharm.